{"organizations": [], "uuid": "9c075a13748d2199d7e111540f41df2a1ed30a00", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/3", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/05/07/globe-newswire-optinose-to-report-first-quarter-2018-financial-results-and-corporate-updates-on-may-14-2018.html", "country": "US", "domain_rank": 767, "title": "Optinose to Report First Quarter 2018 Financial Results and Corporate Updates on May 14, 2018", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.002, "site_type": "news", "published": "2018-05-07T16:00:00.000+03:00", "replies_count": 0, "uuid": "9c075a13748d2199d7e111540f41df2a1ed30a00"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/05/07/globe-newswire-optinose-to-report-first-quarter-2018-financial-results-and-corporate-updates-on-may-14-2018.html", "ord_in_thread": 0, "title": "Optinose to Report First Quarter 2018 Financial Results and Corporate Updates on May 14, 2018", "locations": [], "entities": {"persons": [{"name": "optinose", "sentiment": "negative"}], "locations": [{"name": "pa.", "sentiment": "none"}, {"name": "yardley", "sentiment": "none"}, {"name": "u.s.", "sentiment": "none"}, {"name": "u.s", "sentiment": "none"}], "organizations": [{"name": "company", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "YARDLEY, Pa., May 07, 2018 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will release financial results for the first quarter 2018, before market open on Monday, May 14, 2018.\nMembers of the Company’s leadership team will host a conference call to discuss financial results and corporate updates, including the retail availability of XHANCE TM that commenced in early April 2018. The call is scheduled to start at 8:00 a.m. Eastern Time on Monday, May 14, 2018.\nTo participate on the conference call, please dial (866) 916-4761 from the U.S. or +1 (409) 216-6496 from outside the U.S. In addition, following the completion of the call, a telephone replay will be accessible until May 21, 2018 by dialing (855) 859-2056 from the U.S. or +1 (404) 537-3406 from outside the U.S. and entering conference ID # 6968158. A simultaneous webcast of the call and presentation can be accessed by visiting the Investors section of Optinose’s website at www.optinose.com . In addition, a replay of the webcast will be available on the Company website for 60 days following the event.\nAbout Optinose\nOptinose is a global specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists. Optinose has offices in the U.S., the U.K. and Norway. To learn more, please visit www.optinose.com or follow us on Twitter and LinkedIn .\nOptinose Investor Contact\nJonathan Neely\nJonathan.neely@optinose.com\n267.521.0531\nSource:OptiNose, Inc.", "external_links": ["https://www.globenewswire.com/Tracker?data=T_kL5L4AP7QY0ZVr4cgdj26qLe9oqwRawfKlMECoBck2k524aR3q9d5LLu2Z9xRoGLSQDBhE6KmIVs358noPRO9t612n8nlhe9bq9bmczAE=", "https://www.globenewswire.com/Tracker?data=A94BXVD2gJNAkt5fXoESQizW--DvqliRMesN_vHdljCrbsnxh47zWU2q0e-tU5pUO3E81wXDY2QjjVuEpfLF_AAVI0R_l14g7HOUIX3_3T4=", "https://www.globenewswire.com/Tracker?data=s1JuDMOxvEqwIGgY8mOvf0o8KZDlNObrFZsfKyiQZz1OakOq7Pn5ZgHBdAjiIOQwBzMPWgZfJYQbY2JYczkufw==", "https://www.globenewswire.com/Tracker?data=WSryl9LGZklN5V-oEkqocA0rLbCzGqAGAxcgUyMhIQ0qoxzp8TixO6gF49x5KJn6GLIoxIa_p3WLURKOZhSwyw==", "https://www.globenewswire.com/NewsRoom/AttachmentNg/738ec635-d235-4c49-8d39-0a5636a4b767", "https://www.globenewswire.com/Tracker?data=YR-cEX7w9VPHJMzdS4-iWs9APAPAu1B9o1oKmA3U3S8R8Pj07AuD3mwGYu5tkDnUX-2vTu3F1AI32n58tmQImA==", "https://www.globenewswire.com/Tracker?data=lf0sugq29625lZSbb3a3rp0uM4_QNw5X1PApsq_m7kh9fhGeQahBQ9gmbiaDrsUyE0IrKxa6C63MEPBiHfdqzEEnHwqVYWLv85CDyDd53cPhSi_HMuXr50TYtHqIMyFM", "https://www.globenewswire.com/Tracker?data=WSryl9LGZklN5V-oEkqocOykUyra0WcZBA54AqaEo-8OuOp11_QkSjk88-Qw92c74DW_dueS55U8iW1U2kKinA=="], "published": "2018-05-07T16:00:00.000+03:00", "crawled": "2018-05-07T15:43:44.052+03:00", "highlightTitle": ""}